夢網科技(002123.SZ):子公司中標中移互聯網採購項目 為5G消息體驗的全面覆蓋提供能力支持
格隆匯10月27日丨夢網科技(002123.SZ)公佈,近日,中國移動採購與招標網公示公司全資子公司深圳市夢網科技發展有限公司(以下簡稱"深圳夢網")中標"中移互聯網有限公司2021-2023年內部業務場景短信小程序升級支撐公開比選採購項目"。
此次公司中標"2021-2023年內部業務場景短信小程序升級支撐"項目通過短信小程序補充終端覆蓋規模,同時增強回落後的內容呈現形態和用户體驗,在業務場景方面有效地豐富了服務能力,激發行業創新,助力提升5G消息從"可用"、"易用"到"好用"的業務體驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.